Optimizing balance of treatments in prostate cancer

Optimizing balance of treatments in prostate cancer
Associations of longer duration of androgen deprivation therapy with distant metastasis-free survival and overall survival. A and B, Kaplan-Meier curves for DMFS and OS for patients receiving EBRT+BT and 6 or 18 months of ADT on the RADAR trial. Because the RADAR comparison for patients receiving EBRT+BT is the direct randomization from that trial, unadjusted curves are presented. C and D, Adjusted survival curves for DMFS and OS for the cross-trial comparison between patients receiving ADT for 6 and 18 months (RADAR) vs 28 months (DART). Survival curves were adjusted using an inverse probability treatment weighting approach wherein propensity scores included the following independent variables: treatment type (if relevant), ln(iPSA), clinical T category, Gleason grade group, and age (y) at treatment. Credit: DOI: 10.1001/jamaoncol.2021.6871

Patients receiving radiotherapy to treat high-risk prostate cancer also benefit from androgen deprivation therapy. The ideal duration of treatment may be roughly two years if receiving external beam radiation and one year if receiving external beam radiation with a brachytherapy boost, according to a study published in JAMA Oncology.

The use of (ADT) combined with radiation improves outcomes, but comes with significant side effects including effects on the cardiovascular system, mood, lowered libido and loss of muscle mass. This forces clinicians and patients to weight benefits versus costs for use and duration of treatment with ADT, according to Ashley Ross, MD, Ph.D., associate professor of Urology and a co-author of the study.

"Determining the optimal balance for length of therapy is paramount," said Ross, who is also a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

High-risk cancer is disease with the ability to progress and spread outside of the prostate. When clinically localized prostate cancer is treated with radiation, ADT, which cuts off the androgens that prostate cancer relies on, should be employed to optimize the treatment, according to Ross. Current guidelines suggest 18 to 36 months of ADT, but given its adverse effects, it's commonly administered in shorter durations than indicated. In the current study, investigators sought to determine minimum thresholds of effectiveness as measured by improved survival among patients with high-risk prostate cancer.

The study included one retrospective cohort and two trial cohorts, totaling more than 3,400 patients. The retrospective cohort was assembled by querying databases for patients who received ADT alongside radiotherapy, and the trial cohorts were two studies in which patients were randomized to receive varying durations of ADT alongside radiotherapy, ranging from 4 to 28 months. Patients who received radiation received therapy either with therapy (EBRT) alone or with external beam radiation combined with brachytherapy (seed implants).

Longer durations of ADT were associated with increased survival: Patients receiving EBRT alongside ADT for 28 months had improved survival compared with patients receiving ADT for just 18 months. This can be modified by additional therapies, according to Ross, as patients also undergoing brachytherapy may only need 12 months of ADT to see benefit. However, for other patients, 18 months should be the floor and roughly two years of therapy is preferred.

"For men with high-risk non-metastatic prostate cancer receiving , the optimal length of androgen deprivation is likely over 18 months," Ross said. "Further research to better risk stratify subsets of men with high risk and identify tumors that might be more sensitive to or ADT is ongoing and will lead to more individualized therapeutic regimens that balance cancer control with overall morbidity and quality of life."

More information: Amar U. Kishan et al, Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer, JAMA Oncology (2022). DOI: 10.1001/jamaoncol.2021.6871

Journal information: JAMA Oncology
Citation: Optimizing balance of treatments in prostate cancer (2022, February 28) retrieved 26 May 2024 from https://medicalxpress.com/news/2022-02-optimizing-treatments-prostate-cancer.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

New meta-analysis may help guide treatment planning for patients with high-risk prostate cancer


Feedback to editors